Post-transplant hepatocellular carcinoma: balancing immunosuppression and immune checkpoint inhibitors
Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 580-598
DOI: 10.3350/cmh.2025.1179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Tomoharu Yamada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Liver Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labor, and Welfare of Japan, JSPS KAKENHI.
Abstract (Originalsprache)
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and hepatocellular carcinoma (HCC). Advances in surgical techniques and immunosuppressive regimens have markedly improved early post-transplant survival. However, long-term outcomes remain compromised by HCC recurrence, chronic rejection, metabolic complications, and de novo malignancies. Recurrence of HCC after LT remains a major clinical challenge, with available prognostic models providing limited accuracy in risk stratification. Simultaneously, systemic therapies for unresectable HCC have rapidly advanced, particularly with immune checkpoint inhibitors (ICIs), providing new opportunities and unique challenges in transplant settings. With ICIs carrying a risk of acute and potentially fatal rejection and lacking controlled data on efficacy or safety in the post-transplant setting, tyrosine kinase inhibitors currently represent a standard option for post-transplant recurrence. Novel biomarkers, such as donor-derived cell-free DNA and the gut microbiome, are emerging as potential tools to refine risk stratification and guide immunosuppression. Furthermore, innovative immunotherapies, including oncolytic viruses and mRNA vaccines, are being explored as tumor-specific approaches. Collectively, these advances may reshape future management of LT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Förderung
- Ministry of Health, Labor, and Welfare of Japan
- JSPS KAKENHI
Zitieren
APA
Yamada, T., Tateishi, R., & Fujishiro, M. (2026). Post-transplant hepatocellular carcinoma: balancing immunosuppression and immune checkpoint inhibitors. Clinical and Molecular Hepatology, 32(2), 580-598. https://doi.org/10.3350/cmh.2025.1179
Vancouver
Yamada T, Tateishi R, Fujishiro M. Post-transplant hepatocellular carcinoma: balancing immunosuppression and immune checkpoint inhibitors. Clinical and Molecular Hepatology. 2026;32(2):580-598. doi:10.3350/cmh.2025.1179
BibTeX
@article{Yamada2026,
author = {Yamada, Tomoharu and Tateishi, Ryosuke and Fujishiro, Mitsuhiro},
title = {Post-transplant hepatocellular carcinoma: balancing immunosuppression and immune checkpoint inhibitors},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {2},
pages = {580--598},
doi = {10.3350/cmh.2025.1179}
}
EUVIMED